BASi Shares Improved Strategy for Enhanced Bioequivalence

Pharmaceutical Investing

Bioanalytical Systems announced a new strategy for the potential enhancement their in vitro and in vivo bioequivalence capabilities.

Bioanalytical Systems (NASDAQ:BASI) announced a new strategy for the potential enhancement their in vitro and in vivo bioequivalence capabilities.
As quoted in the press release:

Over the next several months, BASi will hire additional Principal Investigators and Research Analysts to support the company’s Bioanalytical and Pharm Analysis labs, and provide expanded cross training for current staff. Additionally, capital investments are being made for new and upgraded automated dissolution apparatus equipment for the company’s Pharm Analysis labs. These upgrades will not only provide improved data, a commitment at the heart of BASi’s pledge to its clients, but will increase capacity as well. The company will also increase its already extensive library of validated analytical methods applicable to in vivo bioequivalence studies.
BASi has extensive experience in performing in vitro bioequivalence studies as described in regulatory guidances and demonstrated by successful regulatory audits of the company’s work. BASi is actively engaged in developing new methods to be utilized for recent, new guidances. Some of the products requiring in vitro bioequivalence testing include sevelamer carbonate and hydrochloride, lanthanum carbonate, cholestyramine powder, colesevelam hydrochloride, calcium carbonate and colestipol.

Click here to read the full press release.

Source: www.accesswire.com

The Conversation (0)
×